Virus Hybrid Vectored Particles Carrying an RNA Coding for Rabies Virus Glycoprotein
Abstract
Introduction: This study was aimed at establishing a system for producing virus hybrid vectored particles (VHVP) capable of carrying the RNA of the rabies virus glycoprotein (VHVP-RVGP).
Method: To produce VHVP-RVGP, HEK 293T cells were co-transfected with pCMV-Gag-Pol (from leukemia murine virus), pCMV-E1E2 (glycoproteins of hepatitis C virus), and pCMV-RVGP. VHVP-RVGP were collected 48 hours post-co-transfection and titrated by quantitative RT-PCR (RTq-PCR). The RVGP expression was detected by ELISA in lysates of Huh-7 cells treated with VHVP-RVGP.
Results: RT-qPCR assays that were conducted for the detection of cell attachment, as well as entry of VHVP-RVGP, revealed that only a small part was able to enter Huh-7 cells, indicating a limitation in the transduction process. Western blotting assays showed that MLV’s Gag-Pol protein production as well as the incorporation of HCV E1E2 into VHVP were successful.
Conclusion: In conclusion, the data demonstrated that the VHVP system was efficient in carrying the RNA-RVGP, although the HCV E1 and E2 incorporation was not efficiently presented for a proper VHVP conformation.
How to cite this article:
Bernardino TC, Suarez SFP, Pereira CA, Astray
RM, Coroadinha AS, Soares H, Jorge SAC. Virus
Hybrid Vectored Particles Carrying an RNA
Coding for Rabies Virus Glycoprotein. APCRI J.
2023;25(2):1-7.
DOI: https://doi.org/10.24321/0973.5038.202308
References
World Health Organization [Internet]. Rabies; 2016 [cited 2017 Jan 11]. Available from: https://www.afro. who.int/health-topics/rabies
Perrin P, Thibodeau L, Sureau P. Rabies immunosome (subunit vaccine) structure and immunogenicity.
Pre- and post-exposure protection studies. Vaccine. 1985;3(3):325-32. [PubMed] [Google Scholar]
Astray RM, Jorge SA, Pereira CA. Rabies vaccine development by expression of recombinant viral glycoprotein. Arch Virol. 2017;162(2):323-32. [PubMed] [Google Scholar]
Sakamoto S, Ide T, Tokiyoshi S, Nakao J, Hamada F, Yamamoto M, Grosby JA, Ni Y, Kawai A. Studies on the structures and antigenic properties of rabies virus glycoprotein analogues produced in yeast cells. Vaccine. 1999;17(3):205-18. [PubMed] [Google Scholar]
Benmaamar R, Astray RM, Wagner R, Pereira CA. High- level expression of rabies virus glycoprotein with the
RNA-based Semliki Forest Virus expression vector. J Biotechnol. 2009;139(4):283-90. [PubMed] [Google Scholar]
Ramya R, Subramanian BM, Sivakumar V, Senthilkumar RL, Rao KR, Srinivasan VA. Expression and solubilization of insect cell-based rabies virus glycoprotein and assessment of its immunogenicity and protective efficacy in mice. Clin Vaccine Immunol. 2011;18(10):1673-9. [PubMed] [Google Scholar]
Tan SL, editor. Hepatitis C viruses: genomes and molecular biology [Internet]. Horizon Bioscience; 2006 [cited 2016 Aug 3]. Available from: http://www. ncbi.nlm.nih.gov/books/NBK1613/ [PubMed] [Google Scholar]
Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med. 2003;197(5):633-42. [PubMed] [Google Scholar]
Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem. 2003;278(43):41624- 30. [PubMed] [Google Scholar]
Puglia AL, Rezende AG, Jorge SA, Wagner R, Pereira CA, Astray RM. Quantitative RT-PCR for titration of replication-defective recombinant Semliki Forest virus. J Virol Methods. 2013;193(2):647-52. [PubMed] [Google Scholar]
Roldão A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines. 2010;9(10):1149-76. [PubMed] [Google Scholar]
